BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Alembic Pharmaceuticals Ltd.’s reported Q1 FY22 performance below our estimates with lower U.S. sales and weak Ebitda margin, despite strong growth in India business.
Revenue in U.S. was below expectation at ~$50 million due to competitive pressure in sartans and theophylline which led to significant price erosion.
Consolidated revenues declined 1.1% YoY to Rs 13.3 billion (our estimate: Rs 12.8 billion), adjusted profit declined 45.4% YoY to Rs 1.6 billion (our estimate: Rs 2.2 billion) and Ebitda margin dropped 1260 basis points YoY to 17.8% (our estimate: 25%).
We believe near term outlook remains muted due to significant erosion in U.S. sales which would also weigh on Alembic Pharma’s margin.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.